Biologics for asthma and risk of pneumonia
CONCLUSIONS: Mepolizumab, omalizumab and benralizumab, but not dupilumab, were associated with high odds of reporting pneumonia. Our results represent only potential associations between these biologics and pneumonia but not causality. The nature of the FAERS database is such that the cause of the reported events is uncertain. Therefore, we can only roughly estimate the incidence of AEs by the signal strength (ROR value). Nevertheless, although causality could not be assessed, the signal from our study is interesting. We believe it deserves to be further substantiated by real-world studies with robust designs.PMID:38294705...
Source: Journal of Asthma - January 31, 2024 Category: Respiratory Medicine Authors: Maria Gabriella Matera Josuel Ora Luigino Calzetta Paola Rogliani Mario Cazzola Source Type: research
Omalizumab used to treat bullous pemphigoid resistant to other treatments
Br J Dermatol. 2024 Jan 23;190(2):e23. doi: 10.1093/bjd/ljad510.NO ABSTRACTPMID:38262596 | DOI:10.1093/bjd/ljad510 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - January 23, 2024 Category: Dermatology Source Type: research
Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma
For patients with moderate-to-severe persistent allergic asthma, omalizumab is approved for subcutaneous administration according to a recommended dosing table based on weight and total immunoglobulin E (IgE) level. The aim of this analysis was to assess asthma outcomes including quality of life in patients with allergic asthma initiated on omalizumab in the PROSPERO trial; patients were stratified by where their IgE and body weight fell on the approved dosing table. Patient groups were defined as Inside Dosing Table: patients whose IgE and weight fell within the approved dosing table (n = 506); Insufficient Data to R...
Source: Respiratory Medicine - January 20, 2024 Category: Respiratory Medicine Authors: Nicole M. Chase, Monica Littlejohn, Cecile T.J. Holweg, Lauren A. Millette, Arpamas Seetasith, John W. Steinke, Benjamin L. Trzaskoma, Nicola A. Hanania, Thomas B. Casale Tags: Short communication Source Type: research
Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience
CONCLUSION: Among children and adolescents with severe eosinophilic asthma ineligible for or not responsive to omalizumab, mepolizumab therapy exhibited significant reduction in rate of asthma-related hospitalizations and significant decrease in daily steroid dosage.PMID:38240489 | DOI:10.1080/02770903.2024.2303767 (Source: Journal of Asthma)
Source: Journal of Asthma - January 19, 2024 Category: Respiratory Medicine Authors: Y T Lim T C Williams R J Langley E Weir Source Type: research
Efficacy of omalizumab in adult patients with allergic bronchopulmonary aspergillosis: a multicentre study in China
AbstractDespite conventional glucocorticoid and antifungal therapy, acute exacerbation and hospitalization occur frequently in patients with allergic bronchopulmonary aspergillosis (ABPA). Whether omalizumab is an effective and safe treatment for adult patients with ABPA complicating asthma. Patients with ABPA complicating asthma who were treated with omalizumab from October 2019 to May 2023 were collected from five tertiary hospitals and evaluated. The frequencies of acute exacerbation and hospitalization; the number of eosinophils; the total IgE levels; and the average monthly medical dosages after 3, 6, and 12 months ...
Source: Clinical and Experimental Medicine - January 19, 2024 Category: Research Source Type: research
Exosomes From IgE-Stimulated Mast Cells Aggravate Asthma-Mediated Atherosclerosis Through circRNA CDR1as-Mediated Endothelial Cell Dysfunction in Mice
CONCLUSIONS: Exosomes from IgE-stimulated MCs aggravated atherosclerosis through circular RNA CDR1as-mediated endothelial dysfunction, providing a novel insight into asthma-mediated atherosclerosis and potential diagnostic and therapeutic targets.PMID:38235556 | DOI:10.1161/ATVBAHA.123.319756 (Source: Arteriosclerosis, Thrombosis and Vascular Biology)
Source: Arteriosclerosis, Thrombosis and Vascular Biology - January 18, 2024 Category: Cardiology Authors: Hongqin Yang Junye Chen Siyang Liu Yunfei Xue Zhiwei Li Tao Wang Liqun Jiao Qi An Bao Liu Jing Wang Hongmei Zhao Source Type: research
Management of Atopy with Dupilumab and Omalizumab in CADINS Disease
In conclusion, treatment with dupilumab and omalizumab for severe, refractory atopic disease in patients with CADINS appears to be effective and well tolerated in patients with CADINS with severe atopy. (Source: Journal of Clinical Immunology)
Source: Journal of Clinical Immunology - January 17, 2024 Category: Allergy & Immunology Source Type: research
Systemic pain relief after omalizumab injection in patient with hypermobile Ehlers –Danlos syndrome: A case report
Symptomatology pre and post Omalizumab treatment. Key Clinical MessageOmalizumab may be a beneficial adjunct treatment option for hEDS patients require to improve pain control, ability to perform ADLs and functionality and social engagement, and most importantly, quality of life. (Source: Clinical Case Reports)
Source: Clinical Case Reports - January 12, 2024 Category: General Medicine Authors: Sarahrose Jonik,
Andrew Joseph Rothka,
Neyha Cherin Tags: CASE REPORT Source Type: research
Omalizumab improves sleep and health status for patients with chronic rhinosinusitis with nasal polyps: An analysis of randomized clinical trials
ConclusionOmalizumab improved sleep and self-reported health status in patients with CRSwNP. This contributes to evidence that omalizumab provides value for patients beyond the reduction of sinonasal symptoms. (Source: International Forum of Allergy and Rhinology)
Source: International Forum of Allergy and Rhinology - January 11, 2024 Category: Allergy & Immunology Authors: Eli O. Meltzer,
Joaquim Mullol,
Jinnie Ko,
Rebecca Saenz,
John W. Steinke,
Lauren A. Millette,
Philippe Gevaert Tags: ORIGINAL ARTICLE Source Type: research
Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes
This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management and outcomes, and characterized omalizumab response with the use of the high-affinity immunoglobulin E (IgE) receptor (FcεRI) and the Urticaria Control Test. An observational, unicentric, ambispective study was conducted from 2007 to 2023. Solar urticaria was diagnosed in 41 patients with a median follow-up of 60 months. Thirteen patients were prescribed omalizumab, with a median treatment time of 48 months. A significant decrease in FcεRI baseline levels and subsequent median i...
Source: Acta Dermato-Venereologica - January 8, 2024 Category: Dermatology Authors: David Pesqu é Andrea Ciudad Evelyn Andrades Dulce Soto Ramon Gimeno Ramon M Pujol Ana M Gim énez-Arnau Source Type: research
Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes
This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management and outcomes, and characterized omalizumab response with the use of the high-affinity immunoglobulin E (IgE) receptor (FcεRI) and the Urticaria Control Test. An observational, unicentric, ambispective study was conducted from 2007 to 2023. Solar urticaria was diagnosed in 41 patients with a median follow-up of 60 months. Thirteen patients were prescribed omalizumab, with a median treatment time of 48 months. A significant decrease in FcεRI baseline levels and subsequent median i...
Source: Acta Derm Venereol A... - January 8, 2024 Category: Dermatology Authors: David Pesqu é Andrea Ciudad Evelyn Andrades Dulce Soto Ramon Gimeno Ramon M Pujol Ana M Gim énez-Arnau Source Type: research
Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes
This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management and outcomes, and characterized omalizumab response with the use of the high-affinity immunoglobulin E (IgE) receptor (FcεRI) and the Urticaria Control Test. An observational, unicentric, ambispective study was conducted from 2007 to 2023. Solar urticaria was diagnosed in 41 patients with a median follow-up of 60 months. Thirteen patients were prescribed omalizumab, with a median treatment time of 48 months. A significant decrease in FcεRI baseline levels and subsequent median i...
Source: Acta Derm Venereol A... - January 8, 2024 Category: Dermatology Authors: David Pesqu é Andrea Ciudad Evelyn Andrades Dulce Soto Ramon Gimeno Ramon M Pujol Ana M Gim énez-Arnau Source Type: research
Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes
This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management and outcomes, and characterized omalizumab response with the use of the high-affinity immunoglobulin E (IgE) receptor (FcεRI) and the Urticaria Control Test. An observational, unicentric, ambispective study was conducted from 2007 to 2023. Solar urticaria was diagnosed in 41 patients with a median follow-up of 60 months. Thirteen patients were prescribed omalizumab, with a median treatment time of 48 months. A significant decrease in FcεRI baseline levels and subsequent median i...
Source: Acta Dermato-Venereologica - January 8, 2024 Category: Dermatology Authors: David Pesqu é Andrea Ciudad Evelyn Andrades Dulce Soto Ramon Gimeno Ramon M Pujol Ana M Gim énez-Arnau Source Type: research
Highly purified charge variants of a proposed biosimilar to Omalizumab: impact on in vitro potency and stability under thermal stress
In this study, highly purified charge variants cluster (acidic, main peak and basic) of biosimilar product of Xolair were assessed for their impact on in vitro potency and stability at different thermal stress conditions (2-8 °C and - 20 °C). The study data indicating purified charge variants (> 90%) have no impact on in vitro potency and are stable at different thermal stress conditions up to a week.PMID:38156991 | DOI:10.1007/s00449-023-02944-8 (Source: Bioprocess and Biosystems Engineering)
Source: Bioprocess and Biosystems Engineering - December 29, 2023 Category: Biomedical Engineering Authors: Tarun Gupta Sriram Seshadri Source Type: research
Highly purified charge variants of a proposed biosimilar to Omalizumab: impact on in vitro potency and stability under thermal stress
In this study, highly purified charge variants cluster (acidic, main peak and basic) of biosimilar product of Xolair were assessed for their impact on in vitro potency and stability at different thermal stress conditions (2-8 °C and - 20 °C). The study data indicating purified charge variants (> 90%) have no impact on in vitro potency and are stable at different thermal stress conditions up to a week.PMID:38156991 | DOI:10.1007/s00449-023-02944-8 (Source: Bioprocess and Biosystems Engineering)
Source: Bioprocess and Biosystems Engineering - December 29, 2023 Category: Biomedical Engineering Authors: Tarun Gupta Sriram Seshadri Source Type: research
